Gonadotropin-Induced Ovarian Cancer Cell Migration and Proliferation Require Extracellular Signal-Regulated Kinase 1/2 Activation

Strategic Insights -

Gonadotropin hormones, specifically Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), have been shown to stimulate the migration and proliferation of ovarian cancer cells. Australian researchers, led by I. Mertens-Walker from the University of Sydney, Kolling Institute of Medical Research, conducted an in-depth study on the effects of gonadotropins on ovarian cancer cells. The study revealed that gonadotropins activate the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 1/2 (ERK1/2) pathway, leading to increased cell migration and proliferation.

Key Takeaways:

  • Gonadotropin hormones, FSH and LH, activate the ERK1/2 pathway in ovarian cancer cells, leading to increased cell migration and proliferation.
  • Calcium ion signaling is crucial in the ERK1/2 activation process, with treatments that inhibit calcium influx or release effectively blocking ERK1/2 activation.
  • The cAMP/protein kinase A (PKA) pathway is not involved in the mediation of gonadotropin action, as gonadotropins do not increase intracellular cAMP formation and inhibition of PKA does not affect ERK1/2 phosphorylation.
  • Protein kinase C (PKC) delta is essential in the gonadotropin signaling cascade, as its inhibition and downregulation significantly reduce ERK1/2 activation and cell migration.
  • Various inhibitors, including PD98059, verapamil, GF 109203X, and rottlerin, can effectively block gonadotropin-induced cell migration and proliferation by inhibiting the ERK1/2 activation pathway.
  • Small interfering RNA (siRNA)-mediated downregulation of PKCdelta further highlights the importance of this enzyme in the gonadotropin signaling cascade.

Statistics:

  • Ovarian cancer affects approximately 150,000 women worldwide annually, with over 75% of cases diagnosed as epithelial ovarian cancer (EOC).
  • The study focused on two EOC cell lines, OV207 and OVCAR-3, which responded to gonadotropin treatment by increasing ERK1/2 activation and subsequent cell migration and proliferation.
  • The research indicated that gonadotropin treatment increased cell migration by 30-40% and cell proliferation by 20-30% compared to control treatments.
  • The inhibitory effects of PD98059, verapamil, GF 109203X, and rottlerin on gonadotropin-induced cell migration and proliferation were observed in both cell lines.

Sources:

  • Mertens-Walker, I., et al. (2010). Gonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}. Endocrine-related Cancer, 17(2), 335-349.
  • Cancer Gene Therapy (no specific date or publication mentioned).